RecruitingPhase 2NCT04793919
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Associazione Italiana Ematologia Oncologia Pediatrica
- Principal Investigator
- Fanco Locatelli, ProfDept. of Pediatric Hematology Oncology - Bambino Gesù Children's Hospital Rome
- Intervention
- Mylotarg(drug)
- Enrollment
- 89 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- Hôpital Universitaire des Enfants Reine Fabiola (Huderf), Brussels, Belgium
- University Hospital Motol, Prague, Czechia
- Pediatrics and Adolescent Medicine Aarhus University Hospital, Aarhus N, Denmark
- CHU de Bordeaux - Hôpital des Enfants, Bordeaux, France
- Universitätsklinikum Essen (AöR) Zentrum für Kinder-und Jugendmedizin Klinik für Kinderheilkunde III, Essen, Germany
- Our Lady's Children's Hospital Crumlin, Dublin, Ireland
- Rappaport Children'S Hospital, Rambam Health Care Campus, Haifa, Israel
- Ospedale "Casa Sollievo della Sofferenza" - UO Oncoematologia Pediatrica, San Giovanni Rotondo, Foggia, Italy
- AOU Policlinico Dipartimento di Pediatria, Bari, Italy
- Ospedale Papa Giovanni XXIII - USS Oncoematologia Pediatrica, Bergamo, Italy
- AOU Policlinico Sant'Orsola-Malpighi - Oncologia ed Ematologia Pediatrica, Bologna, Italy
- Ospedale Pediatrico Microcitemico "A.Cau", Az.Ospedaliera Brotzu - SC Oncoematologia Ped. e Patologia della coagulazione, Cagliari, Italy
- AOU Policlinico Vittorio Emanuele - UOC Ematologia ed Oncologia Pediatrica con TNO, Catania, Italy
- A.O. Universitaria Meyer - DAI Oncoematologia Pediatrica, Florence, Italy
- IRCCS Istituto Gannina Gaslini - Dipartimento di Oncoematologia, Genova, Italy
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04793919 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo